TAO Synergies (TAOX) Net Margin (2025 - 2026)
TAO Synergies' (TAOX) quarterly Net Margin came in at 15410.84% in Q2 2026, up 42928419.0% on a YoY basis from N/an in Q2 2025, and down 1896.38% quarter-over-quarter from 857.88% in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Net Margin (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Net Margin for 2 consecutive years, with 15410.84% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin rose 42928419.0% year-over-year to 15410.84%; the trailing twelve-month figure through Jun 2026 stood at 2856.13% (changed N/A YoY), and the FY2025 full-year result was 9722.37%, changed N/A from the prior year.
- Net Margin declined to 15410.84% in Q2 2026 per TAOX's latest filing, from 857.88% in the prior quarter.
- Across five years, Net Margin topped out at 857.88% in Q1 2026 and bottomed at 444695.03% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | -20,152.98% |
| 10 | TAO Synergies | 30.86 Mn | 30.86 Mn | - | -15,410.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15,410.84% |
| Mar 31, 2026 | 857.88% |
| Dec 31, 2025 | -8,473.20% |
| Sep 30, 2025 | -1,951.34% |
| Jun 30, 2025 | -444,695.03% |